"OncoSil Medical has achieved key milestones, including CE Marking, US FDA breakthrough device designation, and successful completion of the PanCO Study, demonstrating the device’s safety and efficacy. 33% of patients treated with OncoSil became eligible for surgical resection, and 57% saw at least a 50% reduction in tumour volume."
I saw the above on this article - Impressive numbers. The fact that 33% of patients became eligible for surgical resection after using OncoSil's device is a BIG deal. It shows the real-world impact this treatment is having. Plus, a 50% reduction in tumour volume for over half the patients? That is a significant achievement in the fight against pancreatic cancer.
OSL Price at posting:
0.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)